華測檢測(300012.SZ)2019年度淨利潤預增65%-85%
格隆匯1月22日丨華測檢測(300012.SZ)公佈,預計2019年度歸屬於上市公司股東的淨利潤4.45億元-4.99億元,同比增長65%-85%。業績變動原因如下:
1、報告期內,由於國家宏觀政策支撐,檢測市場需求向好,公司的經營情況穩定,營業收入穩健增長。
2、報告期內,歸屬於上市公司股東的淨利潤較上年同期有較大幅度增長,得益於公司堅持高質量發展戰略,圍繞精細化管理深度挖潛,不斷優化內部管理和資源配置,運營效率和盈利水平持續提升。
3、預計非經常性損益對公司淨利潤的影響額約1.2億元,主要是報告期內出售杭州瑞歐股權的處置收益以及政府補助的影響,上年同期非經常性損益為1.01億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.